AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 301 min read$SNDX

SNDX Q3'26 Earnings: EPS estimate is (0.49) USD

Syndax Pharmaceuticals (SNDX) will report Q3'26 earnings on November 2. Analysts expect $81.75M revenue and a loss of $0.49 per share, according to estimates.

Original reporting
tradingview.com
Published Oct 30, 2026, 11:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 11:06 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
SNDX Q3'26 Earnings: EPS estimate is (0.49) USD — source image
Source · tradingview.com
Decision brief

The 30-second read

$SNDXNeutralMed
01

Why it matters

Traders can use the stated consensus revenue and EPS expectations plus the exact release time to plan orders and hedges around the after-hours earnings window.

02

Market read

Consensus expectations and the after-hours release timestamp can influence near-term positioning and implied volatility into the earnings print.

03

What to watch

The article does not include management guidance, pipeline updates, or prior-quarter trends, which are often the real drivers of biotech earnings reactions.

Relevance 4/10Novelty 4/10Timing: Nov 2 after the market close, results expected around 4:01 PM ET.

Background

The piece is an earnings preview for Syndax Pharmaceuticals’ Q3'26 report scheduled for Nov 2 after the close.

Company-level read

Ticker impact

$SNDXNeutralMedium confidence
Context

Syndax Pharmaceuticals is scheduled to report Q3'26 results Nov 2 after the close, with consensus EPS expected at (0.49) and revenue at $81.75M.

Expected impact

Likely volatility around the Nov 2 after-hours earnings release as traders compare the actual EPS and revenue to the stated consensus expectations.

Evidence & confidence

The article provides only expected figures and timing, not an actual earnings outcome or new guidance; the main tradable element is event-driven positioning into the scheduled report.

Market effects

Sector

Biotech earnings calendar item, but no sector-wide read-through is provided beyond one company’s expected print.

Regional

Primarily US after-hours event risk for biotech investors.

Global

Limited, as the catalyst is company-specific and no cross-market policy or macro linkage is mentioned.

Counterpoint

What could challenge this read

If the stock already priced in the consensus expectations, the after-hours reaction may be muted unless results or guidance materially deviate.

Key entities

  • company
    Syndax Pharmaceuticals, Inc.

    Subject of the earnings preview, scheduled to report Q3'26 results on Nov 2 after the close.

Read at source← All news

Related articles

NOV 2
$SNDXHighAI 8/10

Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update

Syndax Pharmaceuticals Inc (SNDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update • Total revenue of $83.3 million in 3Q26, an 82% year-over-year increase – Revuforj ® (revumenib) net revenue of $60.7 million in 3Q26, a 90% y/y increase, underscores leadership in R/R

SEC EDGAR 8-K2 min
NOV 2
$SNDXLow

Syndax's new finance chief starts Nov. 9; his predecessor stays through year-end

Syndax Pharmaceuticals (SNDX) appointed Aaron A. Ondrey as CFO, effective Nov. 9, 2026. Keith A. Goldan, the outgoing CFO, will stay until year-end to support the transition. Ondrey has 25 years of biotech finance experience, previously serving as CFO at Beren Therapeutics and Rocket Pharmaceuticals. Goldan led Syndax's financial strategy during key growth periods, including FDA approvals for Revuforj and Niktimvo.

stocktitan.net1 min
NOV 2
$SNDXMed

About 20% more patients started Syndax's leukemia drug in Q3 than Q2; new data are expected in Q4.

Syndax Pharmaceuticals reported Q3 2026 revenue of $60.7M for Revuforj and $67.4M for Niktimvo, with Revuforj showing 90% YoY growth. The company expects new data on Revuforj in Q4 2026 from multiple clinical trials and real-world studies. Syndax plans to initiate the RAVEN trial in Q4 2026 and the MenTain trial in Q1 2027. The company will host a conference call today at 4:30 p.m. ET.

stocktitan.net2 min
OCT 14
$SNDXMedAI 8/10

Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal

Syndax Pharmaceuticals' stock fell 15.7% after its Phase II study of axatilimab in idiopathic pulmonary fibrosis (IPF) failed to meet the primary endpoint. The company will discontinue IPF development, but continues cGVHD programs. Axatilimab is already FDA-approved for cGVHD. Year-to-date, SNDX shares have dropped 33.6%.

zacks.com2 min
OCT 13
$CMed

Crude Oil Edges Higher; Citigroup Earnings Top Views

Citigroup (NYSE:C) reported Q3 earnings of $2.85 per share, beating estimates. Bumble (NASDAQ:BMBL) surged 56% after a buyout deal. BIO-Key (NASDAQ:BKYI) rose 139% on a government security contract. Fermi (NASDAQ:FRMI) gained 21% on a credit agreement. Pershing Square (NYSE:PS) fell 11% after a downgrade. Cipher Digital (NASDAQ:CIFR) dropped 14% on a convertible notes offering. Syndax (NASDAQ:SNDX) declined 17% after a trial failure. Oil rose 0.4% to $94.13, while gold and silver fell.

benzinga.com7 min
OCT 13
$SNDXMedAI 8/10

Stifel maintains Syndax stock rating after trial failure

Stifel maintained its Buy rating and $40 price target on Syndax Pharmaceuticals (SNDX) after the company's Phase 2 trial for axatilimab in idiopathic pulmonary fibrosis failed. Syndax will halt further development of the drug for this indication. Stifel noted the setback but kept its positive outlook on Revuforj revenue growth and Niktimvo's potential. SNDX shares fell about 15% post-announcement, trading near their 52-week low.

investing.com2 min